2024年,基石药业延续了上市以来年年亏损的传统,但各项费用得到了有效控制,新的产品也在不断涌现,努力证明着生物科技公司也能够学会用最少的钱、打最硬的仗。3月27日,基石药业(苏州)有限公司(2616.HK,以下简称“基石药业”)在公司官网披露的《2024年年度业绩及公司近期业务进展》显示,录得营业收入4.07亿元,继2023年之后再度收入下滑。净利润继续为负,不过亏损有所收窄,公司上市6年,仍未...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.